Tumor tissue-penetrating peptide specific to neuropilin and fusion protein having same peptide fused therein
A tumor tissue-penetrating peptide specifically binding to neuropilin, or a fusion protein, a small molecule drug, a nanoparticle, or a liposome having the peptide fused therein is provided, as well as a method for preparing the same and a pharmaceutical composition comprising the same for treating, diagnosing, or preventing cancer or angiogenesis-related diseases. The tumor tissue-penetrating peptide is fused to the C-terminus of an anticancer antibody heavy-chain constant region (Fc) and the fused antibody specifically binds to neuropilin, and specifically accumulates in tumor tissue, widens intercellular gaps between tumor vascular endothelial cells, promotes extravasation, increases infiltration within tumor tissue, and shows a remarkably increased in vivo tumor-suppressing activity. Furthermore, the tumor tissue-penetrating peptide is fused into a fusion protein and inhibits the angiogenic function of neuropilin coreceptors resulting from targeting of neuropilin, and is expected to have an alleviating effect on angiogenesis-related diseases.
1. A tumor tissue-penetrating peptide specifically binding to neuropilin, represented by the amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 4.
2. The tumor tissue-penetrating peptide according to claim 1 , wherein the peptide further comprises a linker peptide.
3. The tumor tissue-penetrating peptide according to claim 2 , wherein the linker peptide consists of 1 to 50 amino acids.
4. The tumor tissue-penetrating peptide according to claim 2 , wherein the linker peptide consists of glycine(G), serine(S), or alanine(A).
5. The tumor tissue-penetrating peptide according to claim 2 , wherein the linker peptide consists of the amino acid sequence of (GA)n identified by SEQ ID NO: 11 or (GGGGS)m identified by SEQ ID NO: 12, wherein n and m are each independently an integer between 1 and 20.
6. The tumor tissue-penetrating peptide according to claim 2 , wherein the tumor tissue-penetrating peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5 to SEQ ID NO: 10.
7. A fusion protein having the fused tumor tissue-penetrating peptide of claim 1 fused therein.
8. The fusion protein according to claim 7 , wherein the protein is selected from the group consisting of antibodies, antibody fragments, immunoglobulin, peptides, enzymes, growth factors, cytokine, transcription factors, toxins, antigen peptides, hormones, carrier proteins, motor function proteins, receptors, signaling proteins, storage proteins, membrane proteins, transmembrane proteins, internal proteins, external proteins, secretory proteins, viral proteins, glycoproteins, cleaved proteins, protein complexes, and chemically modified proteins.
9. The fusion protein according to claim 7 , wherein the fusion of tumor tissue-penetrating peptide is mediated by a linker peptide.
10. The fusion protein according to claim 8 , wherein said antibody fragments is a heavy-chain constant region (Fc), an antigen binding fragment (Fab), a single chain variable fragment (scFv), a heavy-chain variable region (VH), a light-chain constant region (CL) or a light-chain variable region (VL) of an antibody.
11. The fusion protein according to claim 8 , wherein the protein is an antibody and a tumor tissue-penetrating peptide is fused to the C-terminus of the heavy-chain constant region (Fc) of the antibody.
12. The fusion protein according to claim 11 , wherein the fusion is mediated by a linker peptide.
13. The fusion protein according to claim 11 , wherein the antibody is selected from the group consisting of IgG, IgM, IgA, IgD and IgE.
14. A nanoparticle having the tumor tissue-penetrating peptide of claim 1 fused therein.
15. The nanoparticle according to claim 14 , wherein the fusion is mediated by a linker peptide.
16. A liposome having the tumor tissue-penetrating peptide of claim 1 fused therein.
17. The liposome according to claim 16 , wherein the fusion is mediated by a linker peptide.
18. A small molecule drug having the tumor tissue-penetrating peptide of claim 1 fused therein.
19. A polynucleotide coding a peptide represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 10.
20. A composition for treating, preventing or diagnosing cancer or angiogenesis-related diseases, comprising the peptide of claim 1 .
21. A composition for treating, preventing or diagnosing cancer or angiogenesis-related diseases, comprising the fusion protein of claim 7 .
22. A method for treating or preventing cancer or angiogenesis-related diseases, comprising administering to a subject in need thereof a composition comprising the peptide of claim 1 .
23. A method for treating or preventing cancer or angiogenesis-related diseases, comprising administering to a subject in need thereof a composition comprising the fusion protein of claim 7 .
24. A composition for treating, preventing or diagnosing cancer or angiogenesis-related diseases, comprising the nanoparticle of claim 14 .
25. A composition for treating, preventing or diagnosing cancer or angiogenesis-related diseases, comprising the liposome of claim 16 .
26. A composition for treating, preventing or diagnosing cancer or angiogenesis-related diseases, comprising the small molecule drug of claim 18 .
27. A method for treating or preventing cancer or angiogenesis-related diseases, comprising administering to a subject in need thereof a composition comprising the nanoparticle of claim 14 .
28. A method for treating or preventing cancer or angiogenesis-related diseases, comprising administering to a subject in need thereof a composition comprising the liposome of claim 16 .
29. A method for treating or preventing cancer or angiogenesis-related diseases, comprising administering to a subject in need thereof a composition comprising the small molecule drug of claim 18 .